| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Insulin degrading enzyme Blocking Peptide for STJ501383 is synthetically produced from the 100-150 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: |
100-150 |
| Specificity: |
This blocking peptide is recommended for use in combination with Insulin degrading enzyme antibody, STJ501383 |
| Immunogen: |
Synthetic peptide taken within amino acid region 100-150 on human Insulin-degrading enzyme protein. |
| Background | Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by APP and IAPP. May play a role in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
